These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Ringe RP; Yasmeen A; Ozorowski G; Go EP; Pritchard LK; Guttman M; Ketas TA; Cottrell CA; Wilson IA; Sanders RW; Cupo A; Crispin M; Lee KK; Desaire H; Ward AB; Klasse PJ; Moore JP J Virol; 2015 Dec; 89(23):12189-210. PubMed ID: 26311893 [TBL] [Abstract][Full Text] [Related]
8. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Ringe RP; Ozorowski G; Yasmeen A; Cupo A; Cruz Portillo VM; Pugach P; Golabek M; Rantalainen K; Holden LG; Cottrell CA; Wilson IA; Sanders RW; Ward AB; Klasse PJ; Moore JP J Virol; 2017 Jun; 91(12):. PubMed ID: 28381572 [TBL] [Abstract][Full Text] [Related]
9. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. Sanders RW; Derking R; Cupo A; Julien JP; Yasmeen A; de Val N; Kim HJ; Blattner C; de la Peña AT; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; van Gils MJ; King CR; Wilson IA; Ward AB; Klasse PJ; Moore JP PLoS Pathog; 2013 Sep; 9(9):e1003618. PubMed ID: 24068931 [TBL] [Abstract][Full Text] [Related]
10. Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Pritchard LK; Vasiljevic S; Ozorowski G; Seabright GE; Cupo A; Ringe R; Kim HJ; Sanders RW; Doores KJ; Burton DR; Wilson IA; Ward AB; Moore JP; Crispin M Cell Rep; 2015 Jun; 11(10):1604-13. PubMed ID: 26051934 [TBL] [Abstract][Full Text] [Related]
11. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Dey AK; Cupo A; Ozorowski G; Sharma VK; Behrens AJ; Go EP; Ketas TJ; Yasmeen A; Klasse PJ; Sayeed E; Desaire H; Crispin M; Wilson IA; Sanders RW; Hassell T; Ward AB; Moore JP Biotechnol Bioeng; 2018 Apr; 115(4):885-899. PubMed ID: 29150937 [TBL] [Abstract][Full Text] [Related]
12. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216 [TBL] [Abstract][Full Text] [Related]
13. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. Guenaga J; de Val N; Tran K; Feng Y; Satchwell K; Ward AB; Wyatt RT PLoS Pathog; 2015 Jan; 11(1):e1004570. PubMed ID: 25569572 [TBL] [Abstract][Full Text] [Related]
14. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265 [TBL] [Abstract][Full Text] [Related]
15. Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein. Ahmed S; Shrivastava T; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK J Biol Chem; 2017 May; 292(20):8236-8243. PubMed ID: 28283570 [TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173 [TBL] [Abstract][Full Text] [Related]
17. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024 [TBL] [Abstract][Full Text] [Related]
19. SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Ringe RP; Colin P; Torres JL; Yasmeen A; Lee WH; Cupo A; Ward AB; Klasse PJ; Moore JP J Virol; 2019 Dec; 94(1):. PubMed ID: 31619555 [TBL] [Abstract][Full Text] [Related]
20. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. Pugach P; Ozorowski G; Cupo A; Ringe R; Yasmeen A; de Val N; Derking R; Kim HJ; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; Julien JP; Burton DR; Wilson IA; Sanders RW; Klasse PJ; Ward AB; Moore JP J Virol; 2015 Mar; 89(6):3380-95. PubMed ID: 25589637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]